封面：溶血磷脂酸受体 1 (LPA1) 拮抗剂作为治疗三阴性乳腺癌的潜在迁移剂（ChemMedChem 16/2024）

IF 3.6 4区医学 Q2 CHEMISTRY, MEDICINAL ChemMedChem Pub Date : 2024-08-20 DOI:10.1002/cmdc.202481601

Dr. Wenjie Liu, Amr A. K. Mousa, Austin M. Hopkins, Yin Fang Wu, Dr. Kelsie L. Thu, Dr. Michael Campbell, Dr. Simon J. Lees, Dr. Rithwik Ramachandran, Dr. Jinqiang Hou

{"title":"封面：溶血磷脂酸受体 1 (LPA1) 拮抗剂作为治疗三阴性乳腺癌的潜在迁移剂（ChemMedChem 16/2024）","authors":"Dr. Wenjie Liu, Amr A. K. Mousa, Austin M. Hopkins, Yin Fang Wu, Dr. Kelsie L. Thu, Dr. Michael Campbell, Dr. Simon J. Lees, Dr. Rithwik Ramachandran, Dr. Jinqiang Hou","doi":"10.1002/cmdc.202481601","DOIUrl":null,"url":null,"abstract":"<p>The Front Cover shows a migrastatic candidate (LPA1 antagonist) that effectively suppresses triple-negative breast cancer (TNBC) migration and invasion, crucial processes leading to secondary tumors. Metastasis is responsible for about 90% of cancer mortality, while migrastatics, devoid of cytotoxicity, present a promising avenue to combat metastasis without inducing drug resistance. The findings offer hope for therapeutic interventions in the formidable realm of triple-negative breast cancer—a highly aggressive subtype. More details can be found in article 10.1002/cmdc.202400013 by Jinqiang Hou and co-workers. Cover design by Prof. Jinqiang Hou.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure>\n </p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202481601","citationCount":"0","resultStr":"{\"title\":\"Front Cover: Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer (ChemMedChem 16/2024)\",\"authors\":\"Dr. Wenjie Liu, Amr A. K. Mousa, Austin M. Hopkins, Yin Fang Wu, Dr. Kelsie L. Thu, Dr. Michael Campbell, Dr. Simon J. Lees, Dr. Rithwik Ramachandran, Dr. Jinqiang Hou\",\"doi\":\"10.1002/cmdc.202481601\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The Front Cover shows a migrastatic candidate (LPA1 antagonist) that effectively suppresses triple-negative breast cancer (TNBC) migration and invasion, crucial processes leading to secondary tumors. Metastasis is responsible for about 90% of cancer mortality, while migrastatics, devoid of cytotoxicity, present a promising avenue to combat metastasis without inducing drug resistance. The findings offer hope for therapeutic interventions in the formidable realm of triple-negative breast cancer—a highly aggressive subtype. More details can be found in article 10.1002/cmdc.202400013 by Jinqiang Hou and co-workers. Cover design by Prof. Jinqiang Hou.\\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure>\\n </p>\",\"PeriodicalId\":147,\"journal\":{\"name\":\"ChemMedChem\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-08-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202481601\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ChemMedChem\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cmdc.202481601\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cmdc.202481601","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

摘要

封面展示的是一种候选的迁移性药物（LPA1 拮抗剂），它能有效抑制三阴性乳腺癌（TNBC）的迁移和侵袭，这是导致继发性肿瘤的关键过程。转移是造成约 90% 癌症死亡的罪魁祸首，而无细胞毒性的移植物抗肿瘤药则为在不诱导耐药性的情况下抗击转移提供了一条大有可为的途径。这些发现为三阴性乳腺癌--一种侵袭性极强的亚型--这一可怕领域的治疗干预带来了希望。更多详情可参见侯金强及其合作者撰写的文章 10.1002/cmdc.202400013。封面设计：侯金强教授。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Front Cover: Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer (ChemMedChem 16/2024)

The Front Cover shows a migrastatic candidate (LPA1 antagonist) that effectively suppresses triple-negative breast cancer (TNBC) migration and invasion, crucial processes leading to secondary tumors. Metastasis is responsible for about 90% of cancer mortality, while migrastatics, devoid of cytotoxicity, present a promising avenue to combat metastasis without inducing drug resistance. The findings offer hope for therapeutic interventions in the formidable realm of triple-negative breast cancer—a highly aggressive subtype. More details can be found in article 10.1002/cmdc.202400013 by Jinqiang Hou and co-workers. Cover design by Prof. Jinqiang Hou.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.